26. The fibrin adhesive granulate in accordance with claim 25, wherein the granulate pellets have a particle size in the range from approximately 100 µm to approximately 200 µm.

27. The fibrin adhesive granulate in accordance with claim 25, wherein said granulate pellets further comprise one or more substances chosen from albumin, fibronectin, or other substances that promote wound healing.

28. The fibrin adhesive granulate in accordance with claim 26, wherein said granulate pellets further comprise one or more substances chosen from albumin, fibronectin, or other substances that promote wound healing.

29. An effervescent preparation comprising a fibrin adhesive granulate as claimed in any one of claims 25 or 27 and substances required for the formation of CO_2, wherein the effervescent preparation generates a foam suitable for hemostasis.

30. The effervescent preparation in accordance with claim 29, wherein the substances required for the formation of CO_2 comprise a mixture of a carbonate and a physiologically safe organic acid.

31. A wound care fleece comprising a biodegradable support medium, wherein the biodegradable support medium comprises a fibrin adhesive granulate as claimed in any one of claims 25 or 27.

32. The wound care fleece in accordance with claim 31, wherein the wound care fleece comprises a hydrophilic, non-aqueous salve base, and wherein said salve base comprises the fibrin adhesive.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

33. The wound care fleece in accordance with claim 31, wherein the biodegradable support medium comprises natural or chemically modified collagen, keratin, gelatin, carbohydrates or cellulose derivatives.

34. The wound care fleece in accordance with claim 31, wherein the biodegradable support medium comprises a polymer chosen from polyhydroxy carboxylic acids, polyesters, polycyano acrylates, polyamino acids, polyalcohols, or silicones.

35. The wound care fleece in accordance with claim 31, wherein said wound care fleece comprises fibrinogen in the range from approximately 0.05 mg/cm^2 to approximately 50 mg/cm^2 and thrombin in the range from approximately 1 µg/cm^2 to approximately 20 mg/cm^2.

36. The wound care fleece in accordance with claim 31, wherein the preparation containing the fibrin adhesive is applied to one or both sides of the support medium.

37. A preparation comprising a fibrin adhesive as claimed in any one of claims 25 or 27.

38. The preparation in accordance with claim 37, wherein said preparation comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.

39. The preparation in accordance with claim 37, wherein said preparation comprises a bandage, wherein said bandage comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

40. The preparation in accordance with claim 37 wherein said preparation comprises a plaster, wherein said plaster comprises a water proof or water permeable material, and wherein said material comprises a wound care fleece, and wherein said wound care fleece comprises a biodegradable support medium comprising the fibrin adhesive.

A1

41. A preparation comprising a wound care fleece as claimed in claim 32.

42. A preparation comprising a hydrophilic, non-aqueous salve base, wherein said salve base comprises a fibrin adhesive as claimed in claim 25.

43. A method for the preparation of a fibrin adhesive granulate as claimed in claim 25 comprising,

suspending the components of the fibrin adhesive in an organic solvent, and spray-drying said suspension to a granulate of particle size in the range from approximately 50 µm to approximately 1000 µm.

44. The method in accordance with claim 43, wherein the particle size of the granulate is in the range from approximately 100 µm to approximately 200 µm.

45. The method in accordance with claim 43, wherein the suspension is spray-dried onto a support medium.

46. The method in accordance with claim 44, wherein the suspension is spray-dried onto a support medium.

47. A method for the preparation of a fibrin adhesive as claimed in claim 25, comprising

preparing a fibrinogen granulate, and

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000

spraying an organic solvent comprising thrombin onto said fibrinogen granulate.

48. The method in accordance with claim 47, wherein a calcium salt is added to the fibrinogen granulate, to the thrombin solution, or to both the fibrinogen granulate and thrombin solution.

A1

49. A method for the preparation of a fibrin adhesive granulate as claimed in claim 25, comprising

preparing separate fibrinogen and thrombin granulates, and

mixing the fibrinogen granulates with the thrombin granulates,

wherein both types of granulates have a particle size in the range from approximately 50 µm to approximately 1000 µm.

50. A method for preparing a preparation comprising layering a fibrin adhesive granulate as claimed in claim 25 on a biodegradable support medium.

51. A method for preparing the preparation as claimed in claim 42 comprising mixing the fibrin adhesive with the hydrophilic, non-aqueous salve base.

52. A method for preparing a preparation comprising adding other biological, vegetable or synthetic active substances to the fibrin adhesive granulate as claimed in claim 25.

53. The method in accordance with claim 51, wherein biological, vegetable or synthetic active substances are chosen from immunoglobulins, chemotherapeutics or antibiotics.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, DC 20005
202-408-4000